Physician profile
Aaron Bremner
NPI 1588335780
$3,233.76
in general payments reported to CMS, 2019-2025
24 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $666 · 2023: $621 · 2024: $715 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $800.00 | 2025 | |
| Janssen Biotech, INC. | $473.03 | 2022-2024 | Erleada |
| Dendreon Pharmaceuticals LLC | $397.98 | 2022-2025 | Provenge |
| Sumitomo Pharma America, INC. | $283.00 | 2023-2025 | Orgovyx, Gemtesa |
| Antares Pharma, INC. | $265.77 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Urovant Sciences INC | $130.25 | 2022 | |
| Astellas Pharma US INC | $113.55 | 2023 | Xtandi, Myrbetriq |
| Tolmar, INC. | $110.44 | 2023-2025 | Eligard, Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $97.66 | 2022-2025 | |
| Immunitybio, INC. | $76.28 | 2024-2025 | |
| Abbvie INC. | $62.02 | 2024-2025 | |
| Teleflex LLC | $59.71 | 2022-2024 | Urolift |
| Merck Sharp & Dohme LLC | $56.12 | 2024 | Keytruda, Lynparza |
| Pfizer INC. | $44.32 | 2022 | |
| Urogen Pharma, INC. | $43.98 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $38.96 | 2024-2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $34.47 | 2022-2024 | Aveed, Xiaflex |
| Boston Scientific Corporation | $29.28 | 2025 | Ams 700 |
| Verity Pharmaceuticals INC. | $27.42 | 2023 | Trelstar |
| Accord Healthcare, INC. | $19.33 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.04 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.93 | 2023 | Yonsa |
| Tolmar Pharmaceuticals, INC. | $17.83 | 2022 | |
| Laborie Medical Technologies Corp. | $15.39 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bremner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.